Colorectal cancer is one of the most common malignant tumors of human digestive tract, ranking third in incidence rate and fifth in mortality among malignant tumors. According to the World Cancer Report 2020, in the past 20 years, the incidence rate of colorectal cancer in China has shown a rapid upward trend, and the incidence is young. Especially in urban areas, in the first tier cities, it is possible to surpass lung cancer and become the new king of cancer.
Although colorectal cancer has a high mortality rate, it is not scary. It takes 5-10 years from the initial stage to eventually mutate into colorectal cancer, and we have sufficient time to discover and treat it. Research has found that gene methylation occurs before cancer and is an important mechanism for cancer development, acting as a "switch" that regulates gene expression. Its stability and consistency are good, making it an ideal means of early screening for cancer. Therefore, abnormal methylation is a distinctive cancer signal. Abnormal gene methylation is closely related to the occurrence of cancer and can be used as a molecular marker for early cancer screening.

1. Target population for colorectal cancer: healthy individuals aged 40 to 74;
2. Opportunity screening: People with high-risk factors for colorectal cancer (family history of colon cancer, history of intestinal surgery, chronic intestinal diseases, etc.) are not subject to age restrictions.

It can assist doctors in managing the entire process of early screening, auxiliary diagnosis, efficacy monitoring, progression monitoring, and prognosis evaluation for colorectal cancer.

1. High precision: Breaking the tradition of only relying on the single judgment of the septin9 gene; Multi gene joint screening to further improve accuracy
2. Safe and non-invasive: non-invasive, only venous blood needs to be extracted for detection
3. Comprehensive evaluation: can be used for preoperative and postoperative evaluation and recurrence monitoring to participate in precise management of colorectal cancer progression
4. Convenient and fast: liquid biopsy, screening at any time, no need to make appointments or queue up